|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 27, 2014 ) Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
The 2013 base-year market sales of asthma products in Australia were $322m. As in the global market, this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as the patent expiry of the best-selling ICS/LABA FDCs, GSK’s Advair and AstraZeneca’s Symbicort, will be offset by eight pipeline product launches, seven of which are targeted biologics.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=214306 .
Scope
Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the Australia from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting the Australia Asthma market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in Australia.
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=214306 . (Report Price: Single User License – US$4995 and Corporate User License – US$14985)
Table of Contents
1 Table of Contents 5
1.1 List of Tables9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 18
3.1.3 Prognosis 20
3.1.4 Quality of Life 20
3.2 Symptoms 21
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 23
4.1.3 Clinical Practice 24
4.2 Australia 29
5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 33
5.3 Inhaled Corticosteroids 37
5.3.1 Flovent (fluticasone propionate) 37
5.3.2 Pulmicort (budenoside) 41
5.3.3 Other Inhaled Corticosteroids 45
5.4 Long-Acting Beta-Agonists 46
5.4.1 Overview 46
5.5 Inhaled Corticosteroids/Long-Acting Beta-Agonists 47
5.5.1 Advair (fluticasone propionate/salmeterol xinafoate) 47
5.5.2 Symbicort (budenoside/formoterol fumarate) 52
5.5.3 Breo Ellipta (fluticasone furoate/vilanterol trifenatate) 56
5.5.4 Dulera (mometasone furoate/formoterol fumarate) 59
5.5.5 Flutiform (fluticasone propionate/formoterol fumarate) 62
5.6 Leukotriene Modifiers 66
5.6.1 Singulair (montelukast) 66
5.6.2 Other Leukotriene Modifiers 70
5.7 Short-Acting Beta-Agonists 71
5.7.1 Overview 71
5.7.2 Efficacy 72
5.7.3 Safety 73
5.8 Targeted Therapies 74
5.8.1 Xolair (omalizumab) 74
5.9 Anticholinergics 77
5.9.1 Spiriva (tiotropium bromide) 77
6 Unmet Need and Opportunity 82
6.1 Overview 82
6.2 Personalized Therapies to Control Severe Asthma 83
6.2.1 Unmet Need 83
6.2.2 Gap Analysis 84
6.2.3 Opportunity 84
6.3 Better Patient Compliance 84
6.3.1 Unmet Need 84
6.3.2 Gap Analysis 85
6.3.3 Opportunity 86
6.4 Lower Cost of Asthma Medications 86
6.4.1 Unmet Need 86
6.4.2 Gap Analysis 87
6.4.3 Opportunity 87
6.5 Proper Diagnosis of Asthma in Children 87
6.5.1 Unmet Need 87
6.5.2 Gap Analysis 88
6.5.3 Opportunity 88
7 Pipeline Assessment 89
7.1 Overview 89
7.2 Promising Drugs in Clinical Development 91
7.2.1 Fluticasone furoate 92
7.2.2 Cinquil (reslizumab) 96
7.2.3 Bosatria (mepolizumab) 101
7.2.4 Lebrikizumab 106
7.2.5 Benralizumab 111
7.2.6 Dupilumab 116
7.2.7 Quilizumab 122
7.2.8 Tralokinumab 126
8 Market Outlook 131
8.1 Australia 131
8.1.1 Forecast 131
8.1.2 Key Events 136
8.1.3 Drivers and Barriers - Global Issues 136
8.1.4 Drivers and Barriers 139
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
